China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration (NMPA) to conduct an open, multi-center Phase I/IIa study. The study will assess the safety, tolerability, pharmacokinetics, and efficacy of RC88 combined with Junshi Bio’s (HKG: 1877, SHA: 688180) programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), in patients with advanced malignant solid tumors.
Details of the Study
RC88 is an antibody-drug conjugate (ADC) that targets mesothelin (MSLN), a protein often overexpressed in certain types of cancer. The Phase I/IIa study will provide valuable insights into the potential synergistic effects of combining RC88 with Tuoyi, aiming to enhance treatment outcomes for patients with advanced malignant solid tumors.
Significance of the Collaboration
This collaboration between RemeGen and Junshi Bio represents a strategic effort to leverage the strengths of both companies in developing innovative cancer therapies. The study is expected to contribute to the advancement of treatment options for patients with challenging cancer types, potentially improving survival rates and quality of life.-Fineline Info & Tech
